Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals, Inc. (ABOS)
:ABOS
ABOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.86 - $3.36
Previous CloseN/A
Volume101.31K
Average Volume (3M)643.16K
Market Cap
$82.38M
Enterprise Value-$52.79M
Total Cash (Recent Filing)$149.15M
Total Debt (Recent Filing)$29.00M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Aug 12, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding60,573,425
10 Day Avg. Volume324,922
30 Day Avg. Volume643,164
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.17K
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$7.00Price Target Upside414.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StabilityABOS finished 2024 with $231.5M in cash and cash equivalents, sufficient to fund operations into 1H27.
Product DifferentiationThe deal with JCR’s technology may improve Acumen’s antibody delivery, potentially bolstering efficacy while adding another source of product differentiation.
Trial Enrollment SuccessAcumen Pharmaceuticals has completed enrollment for the ALTITUDE AD trial, showing strong interest in their differentiated anti-Abeta immunotherapy.
Bears Say
Financial ConcernsAcumen shares are under pressure largely due to concerns about the financial outlay, despite few risks being seen.
Price Target ReductionThe reevaluation of operational expense assumptions has led to a reduction in the price target from $15 to $11.
Safety Profile IssuesThe subQ formulation of sabirnetug, although showing a decent safety profile, has a very high proportion of mild injection site reactions at around 62.5%.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals, Inc.’s price range in the past 12 months?
Acumen Pharmaceuticals, Inc. lowest stock price was $0.85 and its highest was $3.36 in the past 12 months.
What is Acumen Pharmaceuticals, Inc.’s market cap?
Acumen Pharmaceuticals, Inc.’s market cap is $82.38M.
When is Acumen Pharmaceuticals, Inc.’s upcoming earnings report date?
Acumen Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 12, 2025 which is in 4 days.
How were Acumen Pharmaceuticals, Inc.’s earnings last quarter?
Acumen Pharmaceuticals, Inc. released its earnings results on May 13, 2025. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.726 by $0.246.
Is Acumen Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Acumen Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Acumen Pharmaceuticals, Inc. pay dividends?
Acumen Pharmaceuticals, Inc. does not currently pay dividends.
What is Acumen Pharmaceuticals, Inc.’s EPS estimate?
Acumen Pharmaceuticals, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Acumen Pharmaceuticals, Inc. have?
Acumen Pharmaceuticals, Inc. has 60,573,425 shares outstanding.
What happened to Acumen Pharmaceuticals, Inc.’s price movement after its last earnings report?
Acumen Pharmaceuticals, Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.726. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ABOS
Acumen Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (414.71% Upside)
$7.00 (414.71% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.21%
12-Months-Change
Fundamentals
Return on Equity
-55.68%
Trailing 12-Months
Asset Growth
-32.06%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
ABOS Company Deck
ABOS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Acumen Pharmaceuticals demonstrates significant progress and innovation in their Alzheimer’s treatment development, particularly with the rapid enrollment and innovative biomarker use in their ALTITUDE-AD study, as well as promising results in subcutaneous administration. Despite increased R&D expenses and operating losses, the company's strong financial position and strategic advancements indicate a generally positive outlook.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$7.00
▲(414.71% Upside)
Technical Analysis
Medicinova
―
Assembly Biosciences
―
Rani Therapeutics Holdings
―
Invivyd
―
Genenta Science SpA Sponsored ADR
―
Ownership Overview
27.47% Insiders
10.72% Mutual Funds
38.52% Other Institutional Investors
20.44% Public Companies and
Individual Investors